Naturally occurring B-cell responses to breast cancer

Julia A. Coronella-Wood, Evan M Hersh

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

As demonstrated by the effectiveness of trastuzumab, antibodies against breast cancer antigens are a potentially potent mechanism of tumor control. While trastuzumab is administered exogenously, its efficacy suggests that induction of very high titer antibody responses in vivo might also be therapeutic. Both naturally occurring and vaccine-induced antibody responses to some breast cancer antigens are associated with improved survival in some cases. However, the improvement in survival associated with antibody responses to breast cancer is modest, and tumor regression is not known to be associated with the natural antitumor antibody response, indicating a need for improved understanding of the natural antitumor antibody response. Naturally occurring B-cell responses in the form of serum antibody, tumor reactive lymph node B cells, and tumor-infiltrating B cells have been described, and a variety of breast tumor-associated antigens have been identified based on reactivity of patient antibodies. This review discusses current knowledge of humoral immunity to breast cancer with regard to specific antigens and the basis for their immunogenicity, and the contexts (tumor, lymph node, serum) in which responses are observed. With few exceptions, "tumor-associated anti-gens" identified with naturally occurring antibodies may be overexpressed on tumor but are in fact nonspecific autoantigens. This suggests that while overexpression or aberrant processing can increase immunogenicity in some cases, the immunogenicity of many or even most tumor-associated antigens is a function of expression in tumor or the result of ancillary tumor factors.

Original languageEnglish (US)
Pages (from-to)715-738
Number of pages24
JournalCancer Immunology, Immunotherapy
Volume52
Issue number12
DOIs
StatePublished - Dec 2003

Fingerprint

B-Lymphocytes
Breast Neoplasms
Antibody Formation
Neoplasms
Neoplasm Antigens
Antigens
Antibodies
Lymph Nodes
Neoplasm Antibodies
Survival
Autoantigens
Humoral Immunity
Serum
Vaccines

Keywords

  • Antibody
  • B cell
  • Breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Naturally occurring B-cell responses to breast cancer. / Coronella-Wood, Julia A.; Hersh, Evan M.

In: Cancer Immunology, Immunotherapy, Vol. 52, No. 12, 12.2003, p. 715-738.

Research output: Contribution to journalArticle

Coronella-Wood, Julia A. ; Hersh, Evan M. / Naturally occurring B-cell responses to breast cancer. In: Cancer Immunology, Immunotherapy. 2003 ; Vol. 52, No. 12. pp. 715-738.
@article{458b63e3ab3f4d24abfca88a8d6b05a0,
title = "Naturally occurring B-cell responses to breast cancer",
abstract = "As demonstrated by the effectiveness of trastuzumab, antibodies against breast cancer antigens are a potentially potent mechanism of tumor control. While trastuzumab is administered exogenously, its efficacy suggests that induction of very high titer antibody responses in vivo might also be therapeutic. Both naturally occurring and vaccine-induced antibody responses to some breast cancer antigens are associated with improved survival in some cases. However, the improvement in survival associated with antibody responses to breast cancer is modest, and tumor regression is not known to be associated with the natural antitumor antibody response, indicating a need for improved understanding of the natural antitumor antibody response. Naturally occurring B-cell responses in the form of serum antibody, tumor reactive lymph node B cells, and tumor-infiltrating B cells have been described, and a variety of breast tumor-associated antigens have been identified based on reactivity of patient antibodies. This review discusses current knowledge of humoral immunity to breast cancer with regard to specific antigens and the basis for their immunogenicity, and the contexts (tumor, lymph node, serum) in which responses are observed. With few exceptions, {"}tumor-associated anti-gens{"} identified with naturally occurring antibodies may be overexpressed on tumor but are in fact nonspecific autoantigens. This suggests that while overexpression or aberrant processing can increase immunogenicity in some cases, the immunogenicity of many or even most tumor-associated antigens is a function of expression in tumor or the result of ancillary tumor factors.",
keywords = "Antibody, B cell, Breast cancer",
author = "Coronella-Wood, {Julia A.} and Hersh, {Evan M}",
year = "2003",
month = "12",
doi = "10.1007/s00262-003-0409-4",
language = "English (US)",
volume = "52",
pages = "715--738",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "12",

}

TY - JOUR

T1 - Naturally occurring B-cell responses to breast cancer

AU - Coronella-Wood, Julia A.

AU - Hersh, Evan M

PY - 2003/12

Y1 - 2003/12

N2 - As demonstrated by the effectiveness of trastuzumab, antibodies against breast cancer antigens are a potentially potent mechanism of tumor control. While trastuzumab is administered exogenously, its efficacy suggests that induction of very high titer antibody responses in vivo might also be therapeutic. Both naturally occurring and vaccine-induced antibody responses to some breast cancer antigens are associated with improved survival in some cases. However, the improvement in survival associated with antibody responses to breast cancer is modest, and tumor regression is not known to be associated with the natural antitumor antibody response, indicating a need for improved understanding of the natural antitumor antibody response. Naturally occurring B-cell responses in the form of serum antibody, tumor reactive lymph node B cells, and tumor-infiltrating B cells have been described, and a variety of breast tumor-associated antigens have been identified based on reactivity of patient antibodies. This review discusses current knowledge of humoral immunity to breast cancer with regard to specific antigens and the basis for their immunogenicity, and the contexts (tumor, lymph node, serum) in which responses are observed. With few exceptions, "tumor-associated anti-gens" identified with naturally occurring antibodies may be overexpressed on tumor but are in fact nonspecific autoantigens. This suggests that while overexpression or aberrant processing can increase immunogenicity in some cases, the immunogenicity of many or even most tumor-associated antigens is a function of expression in tumor or the result of ancillary tumor factors.

AB - As demonstrated by the effectiveness of trastuzumab, antibodies against breast cancer antigens are a potentially potent mechanism of tumor control. While trastuzumab is administered exogenously, its efficacy suggests that induction of very high titer antibody responses in vivo might also be therapeutic. Both naturally occurring and vaccine-induced antibody responses to some breast cancer antigens are associated with improved survival in some cases. However, the improvement in survival associated with antibody responses to breast cancer is modest, and tumor regression is not known to be associated with the natural antitumor antibody response, indicating a need for improved understanding of the natural antitumor antibody response. Naturally occurring B-cell responses in the form of serum antibody, tumor reactive lymph node B cells, and tumor-infiltrating B cells have been described, and a variety of breast tumor-associated antigens have been identified based on reactivity of patient antibodies. This review discusses current knowledge of humoral immunity to breast cancer with regard to specific antigens and the basis for their immunogenicity, and the contexts (tumor, lymph node, serum) in which responses are observed. With few exceptions, "tumor-associated anti-gens" identified with naturally occurring antibodies may be overexpressed on tumor but are in fact nonspecific autoantigens. This suggests that while overexpression or aberrant processing can increase immunogenicity in some cases, the immunogenicity of many or even most tumor-associated antigens is a function of expression in tumor or the result of ancillary tumor factors.

KW - Antibody

KW - B cell

KW - Breast cancer

UR - http://www.scopus.com/inward/record.url?scp=0345375313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345375313&partnerID=8YFLogxK

U2 - 10.1007/s00262-003-0409-4

DO - 10.1007/s00262-003-0409-4

M3 - Article

C2 - 12920480

AN - SCOPUS:0345375313

VL - 52

SP - 715

EP - 738

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 12

ER -